Differential Hyperphosphorylation of Tau-S199, -T231 and -S396 in Organotypic Brain Slices of Alzheimer Mice. A Model to Study Early Tau Hyperphosphorylation Using Okadaic Acid
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder of the brain, characterized by extracellular aggregation of beta-amyloid (Aβ) and hyperphosphorylation of tau causing intraneuronal neurofibrillary tangles. There is urgent need to study the interactions between Aβ and tau, especially to solve the question of the pathological cascade. In the present study, we aim to develop a model of organotypic brain slices in which both plaque and tau pathology can be examined. Organotypic brain slices (150 µm thick, coronal, at the hippocampal level) from adult (9 month) wildtype (WT, C57BL/6N) and transgenic AD mice (TG, APP_SweDI) were cultured for 2 weeks. To induce tau hyperphosphorylation 100 nM okadaic acid (OA), 10 µM wortmannin (WM) or both were added to the slices. Hyperphosphorylation of tau was tested at tau-S199, tau-T231 and tau-S396 using Western blot. Our data show that in transgenic mice with plaques a 50 kDa fragment of tau-S396 was hyperphosphorylated and that OA induced hyperphosphorylation of tau-S199. In wildtype mice (without plaques) OA caused hyperphosphorylation of a 50 kDa and a 38 kDa tau-T231 form and a 25 kDa tau-S396 fragment. The NMDA antagonist MK801 (1 µM) did not block these effects. Immunohistochemistry showed diffuse increased tau-S396 and tau-T231-like immunoreactivities at the hippocampal level but no formation of neurofibrillary tangles (NFTs). Confocal microscopy indicated, that pTau-T231 was preferentially located in cytoplasma surrounding nuclei whereas pTau-S396 was found mainly in nerve fibers and strongly associated with plaques. In conclusion we provide a novel in vitro model to study both plaque and tau hyperphosphorylation but not NFTs, which could be useful to study pathological processes in AD and to screen for drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tau in physiology and pathology
Wang, Y., & Mandelkow, E. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2015.1 · Cited by 2,251 · cited 4×
“…the stability of microtubuli via phosphorylation and subsequent axonal transport (Hanger et al., 2009b; Ward et al., 2012; Luna-Munoz et al., 2013; Wang and Mandelkow, 2016), others suggest that the deletion or overexpression of tau did not affect the axonal transport rates both in vivo (Yuan et…”
BackgroundInfluentialDendritic Function of Tau Mediates Amyloid-β Toxicity in Alzheimer's Disease Mouse Models
Ittner, L. M., Ke, Y. D., Delerue, F., Bi, M., Gladbach, A., van Eersel, J., Wölfing, H., Chieng, B. C., Christie, M. J., Napier, I. A., et al. (2010) · Cell · doi:10.1016/j.cell.2010.06.036 · Cited by 1,821 · cited 1×
“In this regard, it is possible that the toxicity of Aβ is linked to dendritic tau (Haass and Mandelkow, 2010; Ittner et al., 2010; Ittner and Götz, 2011).”
BackgroundTau pathology and neurodegeneration
Spillantini, M. G., & Goedert, M. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70090-5 · Cited by 1,133
Augustinack, J. C., Schneider, A., Mandelkow, E.-M., & Hyman, B. T. (2002) · Acta Neuropathologica · doi:10.1007/s004010100423 · Cited by 998 · cited 1×
“Our ex vivo data thus support findings that differences in the tau phosphorylation sites are indeed associated with the severity of neuronal cytopathology in AD and it confirms the assumption that an early hyperphosphorylation of tau at specific epitopes may lead to conformational alterations in the pathological casca…”
ResultTau phosphorylation: the therapeutic challenge for neurodegenerative disease
Hanger, D. P., Anderton, B. H., & Noble, W. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.003 · Cited by 965 · cited 4×
“…on the role of tau: while it is well known that tau regulates the stability of microtubuli via phosphorylation and subsequent axonal transport (Hanger et al., 2009b; Ward et al., 2012; Luna-Munoz et al., 2013; Wang and Mandelkow, 2016), others suggest that the deletion or overexpression of…”
BackgroundInfluentialJin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876 · cited 1×
“Studies about the formation of mutated tau show in contrast that e.g., in frontotemporal dementia formation of tangles is existent without the deposition of Aβ (Jin et al., 2011; Selkoe and Hardy, 2016).”
BackgroundCaspase cleavage of tau: Linking amyloid and neurofibrillary tangles in Alzheimer's disease
Gamblin, T. C., Chen, F., Zambrano, A., Abraha, A., Lagalwar, S., Guillozet, A. L., Lu, M., Fu, Y., Garcia-Sierra, F., LaPointe, N., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1630428100 · Cited by 831
The case for rejecting the amyloid cascade hypothesis
Herrup, K. (2015) · Nature Neuroscience · doi:10.1038/nn.4017 · Cited by 768 · cited 1×
“It is suggested that Aβ triggers a neurodegenerative cascade of inflammation and the formation of NFTs including neuronal death (Turner et al., 2003; Gandy, 2005; Barage and Sonawane, 2015; Herrup, 2015).”
BackgroundPropagation of Tau aggregates and neurodegeneration
Goedert, M., Eisenberg, D. S., & Crowther, R. A. (2017) · Annual Review of Neuroscience · doi:10.1146/annurev-neuro-072116-031153 · Cited by 632 · cited 1×
“However, it is well established that aggregated tau is abnormally hyperphosphorylated in different diseases, including AD, but it is still not clear if phosphorylation is the main activator for aggregation (see also review Goedert et al., 2017).”
BackgroundHuman amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo
Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599
Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease
Barage, S. H., & Sonawane, K. D. (2015) · Neuropeptides · doi:10.1016/j.npep.2015.06.008 · Cited by 579 · cited 1×
“It is suggested that Aβ triggers a neurodegenerative cascade of inflammation and the formation of NFTs including neuronal death (Turner et al., 2003; Gandy, 2005; Barage and Sonawane, 2015; Herrup, 2015).”
BackgroundCaspase activation precedes and leads to tangles
de Calignon, A., Fox, L. M., Pitstick, R., Carlson, G. A., Bacskai, B. J., Spires-Jones, T. L., & Hyman, B. T. (2010) · Nature · doi:10.1038/nature08890 · Cited by 517
Organotypic brain slice cultures: A review
Humpel, C. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.07.086 · Cited by 480
Self-citationNovak, M., Kabat, J., & Wischik, C. M. (1993) · The EMBO Journal · doi:10.1002/j.1460-2075.1993.tb05665.x · Cited by 398 · cited 1×
“Indeed in AD, tau is often truncated at its C terminus by the proteolytic cleavage of tau-G391 (Grundke-Iqbal et al., 1986; Novak et al., 1993).”
BackgroundDavis, J., Xu, F., Deane, R., Romanov, G., Previti, M. L., Zeigler, K., Zlokovic, B. V., & Van Nostrand, W. E. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m312946200 · Cited by 373 · cited 1×
“These mice are fully characterized and develop plaques at the age of 5–6 months (Davis et al., 2004).”
BackgroundAndo, K., Maruko-Otake, A., Ohtake, Y., Hayashishita, M., Sekiya, M., & Iijima, K. M. (2016) · PLOS Genetics · doi:10.1371/journal.pgen.1005917 · Cited by 105 · cited 1×
“Tau has more than 40 possible phosphorylation sites and the phosphorylation is regulated by several kinases and phosphatases (Miyasaka et al., 2010; Ando et al., 2016).”
BackgroundMediators of tau phosphorylation in the pathogenesis of Alzheimer’s disease
Hanger, D. P., Seereeram, A., & Noble, W. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.104 · Cited by 98 · cited 4×
“…on the role of tau: while it is well known that tau regulates the stability of microtubuli via phosphorylation and subsequent axonal transport (Hanger et al., 2009b; Ward et al., 2012; Luna-Munoz et al., 2013; Wang and Mandelkow, 2016), others suggest that the deletion or overexpression of…”
BackgroundInfluentialKim, Y., Choi, H., Lee, W., Park, H., Kam, T.-I., Hong, S.-H., Nah, J., Jung, S., Shin, B., Lee, H., et al. (2016) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.12.006 · Cited by 71 · cited 3×
“In fact a caspase tau-A421 cleaved form (TauC3) has been described, being associated with the formation of NFTs (Rohn et al., 2002; Gamblin et al., 2003; de Calignon et al., 2010; Kim et al., 2016).”
BackgroundMicrotubule destruction induces tau liberation and its subsequent phosphorylation
Miyasaka, T., Sato, S., Tatebayashi, Y., & Takashima, A. (2010) · FEBS Letters · doi:10.1016/j.febslet.2010.06.014 · Cited by 41
Cited by
Alzheimer’s disease: Ablating single master site abolishes tau hyperphosphorylation
Stefanoska, K., Gajwani, M., Tan, A. R. P., Ahel, H. I., Asih, P. R., Volkerling, A., Poljak, A., & Ittner, A. (2022) · Science Advances · doi:10.1126/sciadv.abl8809 · Cited by 128
Can mouse models mimic sporadic Alzheimer’s disease?
Humpel, C., & Foidl, B. (2020) · Neural Regeneration Research · doi:10.4103/1673-5374.266046 · Cited by 56
Self-citationGarcia, G., Pinto, S., Ferreira, S., Lopes, D., Serrador, M. J., Fernandes, A., Vaz, A. R., Mendonça, A. D., Edenhofer, F., Malm, T., et al. (2022) · Cells · doi:10.3390/cells11213377 · Cited by 55
Cytomegalovirus infection induces Alzheimer’s disease-associated alterations in tau
Mody, P. H., Marvin, K. N., Hynds, D. L., & Hanson, L. K. (2023) · Journal of NeuroVirology · doi:10.1007/s13365-022-01109-9 · Cited by 22
Metadata
- Authors
- Foidl, B. M., & Humpel, C.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2018-04-19
- Volume
- 10
- Pages
- 113-113
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2802923405
- Cited by
- 47
- References
- 19
- FWCI
- 2.82
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.